Hemab Therapeutics Holdings, Inc. (COAG) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $685.71M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.75M; Retained Earnings (Accumulated Deficit)USD $-228.69M; Stockholders' Equity Attributable to ParentUSD $454.27M.
- 2026-03-31: Additional Paid in CapitalUSD $6.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-439.00K; Retained Earnings (Accumulated Deficit)USD $-204.54M; Stockholders' Equity Attributable to ParentUSD $-198.62M.
- 2025-12-31: Additional Paid in CapitalUSD $4.92M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $175.00K; Retained Earnings (Accumulated Deficit)USD $-181.86M; Stockholders' Equity Attributable to ParentUSD $-176.63M.
- 2025-06-30: Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m); Stockholders' Equity Attributable to ParentUSD (m).
Hemab Therapeutics Holdings, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Preferred Stock, Value, Outstanding USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $685.71M | $-2.75M | $-228.69M | $454.27M | $-454.27M | (m) | 3 month · $2.02M |
| 2026-03-31 | $6.37M | $-439.00K | $-204.54M | $-198.62M | $-198.62M | $360.07M | 3 month · $1.32M |
| 2025-12-31 | $4.92M | $175.00K | $-181.86M | $-176.63M | $-176.63M | $360.17M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | $-141.47M | (m) | 3 month · $494.00K |
| 2025-03-31 | (m) | (m) | (m) | (m) | $-129.15M | (m) | 3 month · $459.00K |
| 2024-12-31 | (m) | (m) | (m) | (m) | $-115.27M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |